Creative Planning
CRSP icon

Creative Planning’s CRISPR Therapeutics CRSP Stock Holding History

Creative Planning’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,000
Closed -$77K – 1976
2018
Q3 		$77K Buy
+3,000
New +$157K ﹤0.01% 1827

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Creative Planning's CRSP Position: Q1 2026 in Review

Creative Planning increased its CRISPR Therapeutics (CRSP) stake by 40% in Q1 2026, buying an estimated $565K and bringing the position to 37,608 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Creative Planning first reported a position in CRSP in Q4 2017 and has held it in 32 quarters since. The position peaked at $1.92M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Creative Planning held 37,608 shares of CRISPR Therapeutics worth $1.79M as of Q1 2026.
  • Creative Planning bought 10,719 CRISPR Therapeutics shares in Q1 2026, an estimated $565K.
  • CRISPR Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1986 holding.
  • Creative Planning first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 32 quarters since.
  • Creative Planning's CRISPR Therapeutics position peaked at $1.92M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.